Contemporary Pediatrics

NEW TODAY: The Centers for Disease Control and Prevention's ACIP has voted to pass a pair of updated recommendations related to the #hepatitis B virus vaccine and timing among infants. View the exact voting language and how the committee voted, here: https://lnkd.in/gRhssn5C

The open-label trial will assess safety, tolerability, pharmacodynamics, and preliminary efficacy in adults before expanding into a pediatric cohort. Earlier FDA rare pediatric disease and orphan designations highlight the significant unmet need for durable, immune-restoring treatments in X-CGD. #Pediatrics #Immunology #RareDisease #GeneTherapy READ MORE:

In an update to a page of the Centers for Disease Control and Prevention's website related to #autism and #vaccines, the CDC now states the following: "The claim 'vaccines do not cause autism' is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism." We have complete coverage of this update, reaction from Susan Kressly, MD, FAAP of the American Academy of Pediatrics, Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, and related vaccine hesitancy comments from Paul Offit MD at the link below. READ MORE: https://lnkd.in/gncN55Xd

From our coverage of last month's Child Neurology Society Annual Meeting, Olivia Kim-McManus, MD, explains the excitement currently going on in the space related to #genetic testing, therapy, and much more. Watch our full interview and get an idea of how the pediatric #neurology space is evolving: https://lnkd.in/g-DdczMU

New this morning: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the commercial launch of #roflumilast 0.05% for the treatment of mild-to-moderate atopic dermatitis in children aged 2 to 5 years. Arcutis stated the topical formulation will be available in pharmacies this week and that the product is being reviewed by commercial pharmacy benefit managers. At the time of approval, Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, spoke with us about how this approval can impact this patient population. Read more on roflumilast: https://lnkd.in/gK2XJ9RM

Today, the American Academy of Pediatrics released interim guidance related to #autism. The AAP does not recommend the routine use of #leucovorin in children with autism, citing limited evidence. The AAP encourages pediatricians to use shared decision-making with families inquiring about leucovorin while providing clear information about available evidence and potential risks. Kristin Sohl, MD, FAAP, of the AAP's Council on Children with Disabilities Executive Committee comments below. Click here for more background that led to this guidance announcement: https://lnkd.in/gi3rSvA5